New York, USA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Warm Autoimmune Hemolytic Anemia Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Leading Companies - Zenas BioPharma, Sanofi, Johnson & Johnson, Novartis, Incyte, Rigel, Alpine Immune Sciences, Hutchison
The dynamics of the warm autoimmune hemolytic anemia market are anticipated to change in the coming years owing to the rise in demand for the development of combination therapies and anemia therapeutics in patient assistance programs is also expected to drive the global wAIHA market.
DelveInsight’s Warm Autoimmune Hemolytic Anemia Market Insights report includes a comprehensive understanding of current treatment practices, wAIHA emerging drugs, market share of individual therapies, and current and forecasted warm autoimmune hemolytic anemia market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Warm Autoimmune Hemolytic Anemia Market Report
- As per DelveInsight’s analysis, the wAIHA market size was found to be USD 505 million in 2022 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight estimates, the total 7MM prevalent cases of wAIHA in 2022, were 84K. Among the 7MM, the highest prevalent cases of this disease were seen in the United States, which accounted for approximately 39.89% of the total prevalent cases.
- Leading warm autoimmune hemolytic anemia companies such as Zenas BioPharma, Sanofi, Johnson & Johnson, Novartis Pharmaceuticals, Incyte Corporation, Rigel Pharmaceuticals, Alpine Immune Sciences, Inc., Hutchison Medipharma Limited, and others are developing novel wAIHA drugs that can be available in the warm autoimmune hemolytic anemia market in the coming years.
- Some of the key therapies for wAIHA treatment include Obexelimab, Rilzabrutinib, Nipocalimab, Ianalumab, Parsaclisinib, Fostamatinib disodium, Povetacicept, and others.
Discover which therapies are expected to grab the major wAIHA market share @ Warm Autoimmune Hemolytic Anemia Market Report
Warm Autoimmune Hemolytic Anemia Overview
Warm autoimmune hemolytic anemia (wAIHA) represents a significant concern in the field of psychiatry and is anticipated by the World Health Organisation to become the leading contributor to the disease burden in high-income countries by 2032. Autoimmune hemolytic anemia (AIHA) is characterized by the heightened breakdown of RBCs due to the presence of autoantibodies targeting RBCs, either with or without the involvement of complement activation. These autoantibodies are generated by self-reactive B lymphocytes found in both tissue and the bloodstream, facilitated through collaboration with T-helper lymphocytes.
wAIHA constitutes the most prevalent form of autoimmune hemolytic anemia, accounting for approximately 70–80% of all adult cases and around 50% of pediatric cases. A majority of these cases are categorized as primary due to an unknown cause, while others are considered secondary and are associated with lymphoproliferative syndromes, malignant diseases such as chronic lymphoblastic leukemia (CLL), non-Hodgkin’s lymphoma, and solid tumors.
Warm Autoimmune Hemolytic Anemia Epidemiology Segmentation
The wAIHA epidemiology section provides insights into the historical and current warm autoimmune hemolytic anemia patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The wAIHA market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Prevalent Cases of Autoimmune Hemolytic Anemia
- Prevalent Cases of Warm Autoimmune Hemolytic Anemia
- wAIHA Diagnosed Prevalent Cases
- wAIHA Type-specific Diagnosed Prevalent Cases
- wAIHA Gender-specific Diagnosed Prevalence
Download the report to understand which factors are driving wAIHA epidemiology trends @ Warm Autoimmune Hemolytic Anemia Epidemiological Insights
Warm Autoimmune Hemolytic Anemia Treatment Market
Historically, warm autoimmune hemolytic anemia (wAIHA) was considered a rare autoimmune disorder primarily managed empirically with long-term corticosteroid treatment. Recent informative observational studies and efforts to classify wAIHA as primary or secondary have improved our understanding of its natural history and prognosis. Currently, there are no approved therapies on the market, and treatment options rely solely on addressing symptoms. Management of wAIHA has predominantly been empirical or based on uncontrolled retrospective studies. With increasing insights into the disease’s pathophysiology from animal models, there is potential for testing novel therapeutic approaches targeting auto-reactive B-cells or TH17 cells.
Rituximab, a chimeric monoclonal antibody that specifically targets the CD20 antigen on B lymphocytes, has demonstrated effectiveness in select controlled clinical trials. As a result, it is increasingly being considered as a secondary treatment option. Other options for the third line of treatment encompass Splenectomy or alternative immunosuppressive agents, such as azathioprine, cyclosporine, and mycophenolate. Limited retrospective series indicate that oral immunosuppressants may demonstrate efficacy, but these studies often lack comprehensive information, such as dosage, attainment of steroid independence, and the duration of response. Therefore, systematic or comparative studies are essential. Referral of patients who have not responded to second-line treatments to a specialized tertiary care center may be a suitable course of action.
Learn more about the FDA-approved drugs for wAIHA @ Drugs for wAIHA Treatment
Key Warm Autoimmune Hemolytic Anemia Therapies and Companies
- Obexelimab: Zenas BioPharma
- Rilzabrutinib: Sanofi
- Nipocalimab: Johnson & Johnson
- Ianalumab: Novartis Pharmaceuticals
- Parsaclisinib: Incyte Corporation
- Fostamatinib disodium: Rigel Pharmaceuticals
- Povetacicept: Alpine Immune Sciences, Inc.
To know more about wAIHA clinical trials, visit @ Warm Autoimmune Hemolytic Anemia Treatment Drugs
Warm Autoimmune Hemolytic Anemia Market Dynamics
The dynamics of the wAIHA market are expected to change in the coming years. The surge in research initiatives has paved the way for an expanding array of therapeutic possibilities to combat WAIHA. This encompasses the emergence of fresh immunosuppressive agents, the development of monoclonal antibody formulations, and the promising potential of complement inhibitory medications. Additionally, drugs in advanced stages of clinical trials have demonstrated strong safety and efficacy profiles, likely motivating other significant players to enter the field.
However, several factors are impeding the growth of the wAIHA market. The underlying cause of this disease remains elusive, characterized by an intricate interplay of autoantigens, the complement system, and irregularities in T and B cell functions. Moreover, there is currently no globally recognized consensus on the preferred treatment approach for relapsed patients who do not respond to corticosteroid therapy.
Furthermore, the wAIHA market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the wAIHA market growth.
| Warm Autoimmune Hemolytic Anemia Report Metrics | Details |
| Study Period | 2019–2032 |
| Warm Autoimmune Hemolytic Anemia Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Warm Autoimmune Hemolytic Anemia Market Size in 2022 | USD 505 Million |
| Key Warm Autoimmune Hemolytic Anemia Companies | Zenas BioPharma, Sanofi, Johnson & Johnson, Novartis Pharmaceuticals, Incyte Corporation, Rigel Pharmaceuticals, Alpine Immune Sciences, Inc., Hutchison Medipharma Limited, and others |
| Key Warm Autoimmune Hemolytic Anemia Therapies | Obexelimab, Rilzabrutinib, Nipocalimab, Ianalumab, Parsaclisinib, Fostamatinib disodium, Povetacicept, and others |
Scope of the Warm Autoimmune Hemolytic Anemia Market Report
- Therapeutic Assessment: Warm Autoimmune Hemolytic Anemia current marketed and emerging therapies
- Warm Autoimmune Hemolytic Anemia Market Dynamics: Attribute Analysis of Emerging Warm Autoimmune Hemolytic Anemia Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Warm Autoimmune Hemolytic Anemia Market Access and Reimbursement
Discover more about wAIHA drugs in development @ Warm Autoimmune Hemolytic Anemia Clinical Trials
Table of Contents
| 1. | Warm Autoimmune Hemolytic Anemia Market Key Insights |
| 2. | Warm Autoimmune Hemolytic Anemia Market Report Introduction |
| 3. | Warm Autoimmune Hemolytic Anemia Market Overview at a Glance |
| 4. | Warm Autoimmune Hemolytic Anemia Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Warm Autoimmune Hemolytic Anemia Treatment and Management |
| 7. | Warm Autoimmune Hemolytic Anemia Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Warm Autoimmune Hemolytic Anemia Marketed Drugs |
| 10. | Warm Autoimmune Hemolytic Anemia Emerging Drugs |
| 11. | Seven Major Warm Autoimmune Hemolytic Anemia Market Analysis |
| 12. | Warm Autoimmune Hemolytic Anemia Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Warm Autoimmune Hemolytic Anemia Epidemiology Forecast
Warm Autoimmune Hemolytic Anemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted wAIHA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Warm Autoimmune Hemolytic Anemia Pipeline
Warm Autoimmune Hemolytic Anemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key wAIHA companies, including Immunovant Sciences GmbH, Apellis Pharmaceuticals, Inc., Bioverativ, among others.
Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key iron deficiency anemia companies including Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysi, among others.
Iron Deficiency Anemia Pipeline
Iron Deficiency Anemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key iron deficiency anemia companies, including Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysi, among others.
Cold Agglutinin Disease Market
Cold Agglutinin Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cold agglutinin disease companies including Apellis Pharmaceuticals, Swedish Orphan Biovitrum, Novartis, Incyte Corporation, among others.
Cold Agglutinin Disease Pipeline
Cold Agglutinin Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cold agglutinin disease companies, including Apellis Pharmaceuticals, Swedish Orphan Biovitrum, Novartis, Incyte Corporation, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
